Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Type 1 diabetes (T1D) patients' lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems' efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes.

Automated summary

The introduction of insulin pumps, especially advanced hybrid closed loop systems (AHCL), has greatly impacted the lifestyle and prognosis of Type 1 Diabetes (T1D) patients. Emerging data consistently confirm the improvement in glycemic control due to technological advancements in this disease. The use of these devices not only enhances patients' health but also improves their daily routines. However, limited research exists on the use of new devices in different patient populations, particularly in different age groups and types of diabetes. This review aims to highlight the characteristics and efficacy of each available Automated Insulin Delivery (AID) system for T1D patients, focusing on diverse age groups and populations, such as children and pregnant women.